ArticleJournal of neuro-oncology2013
Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice.
Article in Journal of neuro-oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- Gliosarcoma: A Multi-Institutional Analysis on Clinical Outcomes and Prognostic Factors.Cancer medicine · 2024Article
- Prognostic Factors of Gliosarcoma in the Real World: A Retrospective Cohort Study.Computational and mathematical methods in medicine · 2023Article
- Chasing a rarity: a retrospective single-center evaluation of prognostic factors in primary gliosarcoma.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022Article
- Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.Journal of neuro-oncology · 2022Article
- Prognostic and predictive factors of secondary gliosarcoma: A single-institution series of 18 cases combined with 89 cases from literature.Frontiers in oncology · 2022Article
- The clinical, radiological, and immunohistochemical characteristics and outcomes of primary intracranial gliosarcoma: a retrospective single-centre study.Neurosurgical review · 2021Article
- Evaluating Surgical Resection Extent and Adjuvant Therapy in the Management of Gliosarcoma.Frontiers in oncology · 2020Article
- Prognostic factors among single primary gliosarcoma cases: A study using Surveillance, Epidemiology, and End Results data from 1973-2013.Cancer medicine · 2019Article
- Clinical characteristics and disease-specific prognostic nomogram for primary gliosarcoma: a SEER population-based analysis.Scientific reports · 2019Article
- Gliosarcoma in a Young Filipino Woman: A Case Report and Review of the Literature.The American journal of case reports · 2019Review
- Gliosarcoma: a clinical and radiological analysis of 48 cases.European radiology · 2019Article
- Clinical Characteristics of Gliosarcoma and Outcomes From Standardized Treatment Relative to Conventional Glioblastoma.Frontiers in oncology · 2019Article
- Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma.Journal of neuro-oncology · 2018Article
- Giant parieto-occipital lobe pediatric gliosarcoma: Report of a rare entity and review of literature.Surgical neurology international · 2018Article
- Gliosarcoma in Young Adults: A Rare Variant of Glioblastoma.World journal of oncology · 2017Article
- Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series.Journal of neuro-oncology · 2016Article
- Radiotherapy plus concomitant temozolomide in primary gliosarcoma.Journal of neuro-oncology · 2016Article
- Gliosarcoma with Primary Skull Base Invasion.Case reports in radiology · 2016Article
- Therapeutic management of gliosarcoma in the temozolomide era.CNS oncology · 2015Review
- Primary gliosarcoma with long-survival: report of two cases and review of literature.International journal of clinical and experimental pathology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study is to determine the factors that impact overall survival (OS) in adult patients with gliosarcoma in the modern era treated at a single institution compared with a cohort from the SEER registry. A total of 46 adult patients with pathologically confirmed gliosarcoma at MD Anderson Cancer Center from 2000 to 2010 were retrospectively analyzed. Demographic and treatment were obtained. For comparison, a total of 218 patients with gliosarcoma in the SEER database from 1991 to 2008 were analyzed. Survival analysis was conducted using the Kaplan-Meier log rank test. At MD Anderson, the overall incidence of gliosarcoma over the specified time interval was 1.5 %. Gliosarcoma was more common in males (n = 31, 67.4 %) with a median age of 56 years (range 24-92 years). Median survival in all patients was 12.5 months. A total of 17 patients (37 %) received temozolomide (TMZ) concurrently with RT and adjuvantly, with a 24 month OS of 20.0 %, compared with 10.2 % among those not treated with this regimen (p = 0.68). In contrast, the 2 year OS rate in the SEER database was 24.2 % during 2006-2008, compared to 12.1 % among those diagnosed in 2000-2003 (p = 0.03), presumably related to the widespread adoption of the chemoradiation regimen. Patients with gliosarcoma treated with TMZ at a single institution improved OS although this finding did not reach statistical significance. Patients diagnosed in the TMZ era in the SEER database display an improved OS, although the explanation for this finding requires further elucidation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.